CVAC News
Archived Headlines
- German biotech CureVac prices US IPO at $16 high end 08/14/20
- German biotech CureVac sets terms for $200 million US IPO 08/10/20
- US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week 08/07/20
- US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week 07/24/20
- German biotech CureVac files for a $100 million US IPO 07/24/20
Renaissance Capital's 2020 Global IPO Market Recap
Global IPO Market Achieves Six-Year High Amid Pandemic The global IPO market hit a six-year record in 2020 as pandemic-induced volatility was followed by a swift rebound in the second half....read more
Updated: Renaissance Capital's 2020 US IPO Market Review
The IPO Market Has the Best of Times in the Worst of Times 2020 was a year to forget for many people, but it was unforgettable for IPO investors who benefitted from both the number of IPOs...read more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in...read more
US IPO Weekly Recap: Coronavirus vaccine developer CureVac pops 249% in a 4 IPO week
Four IPOs and six SPACs entered the public markets this past week led by CureVac (CVAC), which posted the largest first-day pop for a US IPO since 2005. German biotech CureVac (CVAC) raised $213 million at a $2.8 billion market cap and...read more